Trial
NCT00671112
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Brian Hill, MD, PhD
Collaborators
National Cancer Institute (NCI); The Leukemia and Lymphoma Society
Condition
714leukemia
Intervention
Bortezomib
Why stopped
Treatment ineffective
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-10-28